Scarica l'app Stockscreener
7.07
2.46%
0.17
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - Insider Monkey
Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune
FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus
Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan
Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus
Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World
Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World
Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada
Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com
Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target - Insider Monkey
Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada
Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN
Mariner LLC Buys Shares of 16,516 Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsFULC - ACCESS Newswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences - The Manila Times
Market Momentum Report: Fulcrum Therapeutics Inc (FULC)’s Negative Close at 5.35 - DWinneX
Lobbying Update: $40,000 of FULCRUM THERAPEUTICS lobbying was just disclosed - Nasdaq
Fulcrum Therapeutics (FULC) to Present PIONEER Data at Upcoming Conference Call | FULC Stock News - GuruFocus
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News
Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance
Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com
Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus
FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus
FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):